PDF(Pubmed)
Abstract：
UNASSIGNED: Nocturnal blood pressure (BP) is correlated with an increased risk of cardiovascular events and is an important predictor of cardiovascular death in hypertensive patients.
UNASSIGNED: Nocturnal BP control is of great importance for cardiovascular risk reduction. This systematic review and meta-analysis aimed to explore the efficacy of angiotensin receptor blockers (ARBs) for nocturnal BP reduction in patients with mild to moderate hypertension.
UNASSIGNED: PICOS design structure was used to formulate the data extraction. All statistical calculations and analyses were performed with R.
UNASSIGNED: Seventy-seven studies with 13,314 participants were included. The overall analysis indicated that nocturnal BP drop varied considerably among different ARBs. Allisartan (13.04 [95% CI (-18.41, -7.68)] mmHg), olmesartan (11.67 [95% CI (-14.12, -9.21)] mmHg), telmisartan (11.11 [95% CI (-12.12, -10.11)] mmHg) were associated with greater reduction in nocturnal systolic BP. In the aspect of the nocturnal-diurnal BP drop ratio, only allisartan was greater than 1. While, the variation tendency of last 4-6 h ambulatory BP was basically consistent with nocturnal BP. Additionally, allisartan showed improvement effect in the proportion of patients with dipping BP pattern.
UNASSIGNED: This study demonstrates that for patients with mild to moderate hypertension, allisartan, olmesartan and telmisartan have more advantages in nocturnal BP reduction among the ARBs, while allisartan can reduce nighttime BP more than daytime BP and improve the dipping pattern.
This meta-analysis explores the efficacy of Angiotensin II AT1 receptor antagonists (ARBs) on nocturnal blood pressure (BP) reduction in mild to moderate hypertension.The results demonstrate that for patients with mild to moderate hypertension, allisartan, olmesartan and telmisartan have more advantages in nocturnal BP reduction among the ARBs.Allisartan can reduce nighttime BP more effectively than daytime BP, which also improve the dipping pattern.
UNASSIGNED: Nocturnal BP control is of great importance for cardiovascular risk reduction. This systematic review and meta-analysis aimed to explore the efficacy of angiotensin receptor blockers (ARBs) for nocturnal BP reduction in patients with mild to moderate hypertension.
UNASSIGNED: PICOS design structure was used to formulate the data extraction. All statistical calculations and analyses were performed with R.
UNASSIGNED: Seventy-seven studies with 13,314 participants were included. The overall analysis indicated that nocturnal BP drop varied considerably among different ARBs. Allisartan (13.04 [95% CI (-18.41, -7.68)] mmHg), olmesartan (11.67 [95% CI (-14.12, -9.21)] mmHg), telmisartan (11.11 [95% CI (-12.12, -10.11)] mmHg) were associated with greater reduction in nocturnal systolic BP. In the aspect of the nocturnal-diurnal BP drop ratio, only allisartan was greater than 1. While, the variation tendency of last 4-6 h ambulatory BP was basically consistent with nocturnal BP. Additionally, allisartan showed improvement effect in the proportion of patients with dipping BP pattern.
UNASSIGNED: This study demonstrates that for patients with mild to moderate hypertension, allisartan, olmesartan and telmisartan have more advantages in nocturnal BP reduction among the ARBs, while allisartan can reduce nighttime BP more than daytime BP and improve the dipping pattern.
This meta-analysis explores the efficacy of Angiotensin II AT1 receptor antagonists (ARBs) on nocturnal blood pressure (BP) reduction in mild to moderate hypertension.The results demonstrate that for patients with mild to moderate hypertension, allisartan, olmesartan and telmisartan have more advantages in nocturnal BP reduction among the ARBs.Allisartan can reduce nighttime BP more effectively than daytime BP, which also improve the dipping pattern.
摘要：
■夜间血压（BP）与心血管事件风险增加相关，并且是高血压患者心血管死亡的重要预测指标。
■夜间血压控制对于降低心血管风险非常重要。本系统评价和荟萃分析旨在探讨血管紧张素受体阻滞剂（ARBs）降低轻中度高血压患者夜间血压的疗效。
■PICOS设计结构用于制定数据提取。所有统计计算和分析均采用R.
■纳入了77项研究，共有13,314名参与者。总体分析表明，不同ARB之间的夜间血压下降差异很大。Allisartan(13.04[95%CI(-18.41,-7.68)]mmHg),奥美沙坦（11.67[95%CI（-14.12，-9.21）]mmHg），替米沙坦(11.11[95%CI(-12.12,-10.11)]mmHg)与夜间收缩压降低幅度相关.在夜间血压下降率方面，只有Allisartan大于1。同时,最后4-6h动态血压的变化趋势与夜间血压基本一致。此外,Allisartan对浸渍BP模式患者的比例有改善作用。
■这项研究表明，对于轻度至中度高血压患者，Allisartan,奥美沙坦和替米沙坦在降低ARBs夜间血压方面更有优势，而Allisartan可以降低夜间血压比白天血压更多，并改善浸渍模式。
这项荟萃分析探讨了血管紧张素IIAT1受体拮抗剂（ARBs）对轻度至中度高血压患者夜间血压（BP）降低的疗效。结果表明，对于轻度至中度高血压患者，Allisartan,奥美沙坦和替米沙坦在降低ARBs夜间血压方面更有优势。Allisartan可以比白天更有效地降低夜间血压，这也改善了浸渍模式。
■夜间血压控制对于降低心血管风险非常重要。本系统评价和荟萃分析旨在探讨血管紧张素受体阻滞剂（ARBs）降低轻中度高血压患者夜间血压的疗效。
■PICOS设计结构用于制定数据提取。所有统计计算和分析均采用R.
■纳入了77项研究，共有13,314名参与者。总体分析表明，不同ARB之间的夜间血压下降差异很大。Allisartan(13.04[95%CI(-18.41,-7.68)]mmHg),奥美沙坦（11.67[95%CI（-14.12，-9.21）]mmHg），替米沙坦(11.11[95%CI(-12.12,-10.11)]mmHg)与夜间收缩压降低幅度相关.在夜间血压下降率方面，只有Allisartan大于1。同时,最后4-6h动态血压的变化趋势与夜间血压基本一致。此外,Allisartan对浸渍BP模式患者的比例有改善作用。
■这项研究表明，对于轻度至中度高血压患者，Allisartan,奥美沙坦和替米沙坦在降低ARBs夜间血压方面更有优势，而Allisartan可以降低夜间血压比白天血压更多，并改善浸渍模式。
这项荟萃分析探讨了血管紧张素IIAT1受体拮抗剂（ARBs）对轻度至中度高血压患者夜间血压（BP）降低的疗效。结果表明，对于轻度至中度高血压患者，Allisartan,奥美沙坦和替米沙坦在降低ARBs夜间血压方面更有优势。Allisartan可以比白天更有效地降低夜间血压，这也改善了浸渍模式。
